良性前列腺增生症中的慢性炎症:病理生理学和治疗选择
1Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
概括
慢性前列腺炎症显著影响良性前列腺激增症 (BPH) 的发展和严重程度. 了解这些机制是开发更好的治疗方法的关键,以改善下泌尿道症状.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 炎症研究 炎症研究
- 病理生理学 病理生理学
背景情况:
- 良性前列腺增生 (BPH) 在老年男性中很常见,导致膀出口阻塞和下泌尿道症状.
- 慢性前列腺炎症越来越多地被认为是BPH病原和进展的贡献者.
研究的目的:
- 本综述探讨了慢性炎症和BPH之间的复杂联系.
- 专注于潜在的机制,临床相关性和当前/替代治疗策略.
主要方法:
- 审查关于BPH病理生理学和炎症的现有文献.
- 分析炎症性细胞因子 (例如IL-17,IL-8) 在前列腺组织重塑中的作用.
- 评估当前BPH疗法及其在炎症前列腺中的局限性.
主要成果:
- BPH病理生理学涉及荷尔蒙变化,缺氧,尿液反流,自身免疫反应和炎症.
- 像IL-17和IL-8这样的特定细胞因子与前列腺组织变化和BPH进展有关.
- 患有慢性炎症的患者往往有严重的症状,可能对标准治疗反应不佳.
结论:
- 慢性前列腺炎症是BPH发展和症状严重程度的核心原因.
- 针对炎症途径为新和更有效的BPH疗法提供了潜力.
- 进一步了解这些机制可以改善患者的生活质量.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Chronic Bowel Disorders: Introduction
439
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
439
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Gastritis-II: Pathophysiology
312
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
312


